Adenocarcinoma of the esophagogastric junction: Incidence, characteristics, and treatment strategies

Gastric Cancer

Volumn 13, Issue 2, 2010, Pages 63-73

  Hasegawa, Shinichi ^a   Yoshikawa, Takaki ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; AGE DISTRIBUTION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EASTERN HEMISPHERE; ESOPHAGOGASTRIC CARCINOMA; ESOPHAGOGASTROSTOMY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERMETHOD COMPARISON; JAPAN; MULTIMODALITY CANCER THERAPY; NETHERLANDS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX RATIO; STOMACH CARCINOMA; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNITED STATES; WESTERN HEMISPHERE; ADENOCARCINOMA; ESOPHAGUS TUMOR; FEMALE; INCIDENCE; LOWER ESOPHAGUS SPHINCTER; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; STOMACH TUMOR;

ADENOCARCINOMA; CLINICAL TRIALS, PHASE III AS TOPIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; INCIDENCE; MALE; PROGNOSIS; STOMACH NEOPLASMS;

EID: 78049299608     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-010-0555-2     Document Type: Review

References (69)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289
3. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: Incidence time trend variability according to morphological subtypes and organ subtypes. Int J Cancer 1997;71:340-344
4. Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: Relevance of a topographic-anatomic subclassification. J Surg Oncol 2005;90: 139-146
6. Siewert JR, Stein HJ. Carcinoma of the cardia: Carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. Dis Esophagus 1996;9:173-182
7. Siewert JR, Stein HJ. Classifi cation of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-1459
8. von Rahden BHA, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol 2006;12: 6608-6613
9. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal refl ux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831
10. Stein HJ, Feith M, Siewert JR. Cancer of the esophagogastric junction. Surg Oncol 2000;9:35-41.
11. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophagogastric junction. Scand J Surg 2006;95:260-269
12. Bai JG, Lv Y, Dang CX. Adenocarcinoma of the esophagogastric junction in China according to Siewert's classification. Jpn J Clin Oncol 2006;36:364-367
13. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-925
14. van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: Deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-752
15. Sarbia M, Borchard F, Hengels KJ. Histogenetical investigations on adenocarcinomas of the esophagogastric junction. An immunohistochemical study. Pathol Res Pract 1993;189:530-535
16. Carrie A. Adenocarcinoma of the upper end of oesophagus arising from ectopic gastric epithelium. Br J Surg 1950;37:474.
17. Smithers DW. Adenocarcinoma of the oesophagus. Thorax 1956; 11:257-267
18. Puestow CB, Gillesby WJ, Guynn VL. Cancer of the esophagus. AMA Arch Surg 1955;70:662-668
19. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881-894
20. Armstrong RA, Blalock JB, Carrera G. Adenocarcinoma of the middle third of the esophagus arising from ectopic gastric mucosa. J Thorac Surg 1959;37:398-403.
21. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146 (Pubitemid 40277094)
22. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99:582-588
23. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev 1992;1:265-269
24. McKinney A, Sharp L, Macfarlane GJ, Muir CS. Oesophageal and gastric cancer in Scotland 1960-1990. Br J Cancer 1995;71:411-415
25. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402-407
26. Moller H. Incidence of cancer of oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1992;1:159-164
27. Liabeuf A, Faivre J. Time trends in oesophageal cancer incidence in Cote d'Or (France), 1976-1993. Eur J Cancer Prev 1997;6:24-30.
28. Levi F, Randimbison L, La Vecchia C. Esophageal and gastric carcinoma in Vaud, Switzerland, 1976-1994. Int J Cancer 1998;75: 160-161
29. Thomas RJ, Lade S, Giles GG, Thursfield V. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust N Z J Surg 1996;66:271-275
30. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Int J Epidemiol 1996;25:941-947
31. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 2008;38:464-468
32. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, et al. Unchanging trend of esophagogastric junction adenocarcinoma in Korea: Experience at a single institution based on Siewert's classification. Dis Esophagus 2009;22:676-681
33. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large referral center in Japan. J Gastroenterol Hepatol 2008;23:1662-1665
34. Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg 2007;134:378-385
35. de Manzoni G, Pedrazzani C, Pasini F, Di Leo A, Durante E, Castaldini G, et al. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg 2002;73:1035-1040
36. Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg 2009;33:95-103.
37. Fang WL, Wu CW, Chen JH, Lo SS, Hsieh MC, Shen KH, et al. Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol 2009;16:3237-3244
38. Lagergren J. Adenocarcinoma of oesophagus: What exactly is the size of the problem and who is at risk? Gut 2005;54(Suppl 1): I1- 5.
39. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction. Results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. Ann Surg 2000;232:353-361
40. Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001;129: 103-109
41. Husemann B. Cardia carcinoma considered as a distinct clinical entity. Br J Surg 1989;76:136-139
42. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: The Japanese approach. Semin Oncol 1996;23:360-368
43. Kodama I, Kofuji K, Yano S, Shinozaki K, Murakami N, Hori H, et al. Lymph node metastasis and lymphadenectomy for carcinoma in the gastric cardia: Clinical experience. Int Surg 1998;83: 205-209
44. Yonemura Y, Tsugawa K, Fonseca L, Fushida S, Matsumoto H, Ninomiya I, et al. Lymph node metastasis and surgical management of gastric cancer invading the esophagus. Hepatogastroenterology 1995;42:37-42.
45. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tissen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669
46. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: 5-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1001.
47. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal transhiatal approach for gastric cancer of the cardia or subcardia; a randomised controlled trial. Lancet Oncol 2006;7:644-651
48. Sasako M, Sano T, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462
49. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Lui WY, et al. Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006;7:309-315
50. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914
51. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732
52. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-1820
53. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: Meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-761
54. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
55. Boige V, Pignon JP, Saint-Aubert B, Lasser T, Conroy O, Bouché P, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of the stomach and lower oesophagus. FNLCC ACCORD 07-FFCD 9703 trial. J Clin Oncol 2007;25:200s (Suppl; abstract 4512).
56. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730
57. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, et al. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004;53:925-930
58. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538-543
59. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera- Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856
60. Kies MS, Rosen ST, Tsang TK, Shetty R, Schneider PA, Wallenmark CB, et al. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 1987; 60:2156-2160
61. Ajani JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCari L, et al. Prolonged chemotherapy for localized squamous cell carcinoma of the esophagus. Eur J Cancer 1992;28A:880-884
62. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG 9407). Jpn J Clin Oncol 2001;31:419-423
63. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15: 261-267
64. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004. (Pubitemid 34413593)
65. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909
66. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997
67. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-221
68. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
69. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, et al. Effi cacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27:18s (Suppl; abstract LBA4509).